TABLE 1

Effect of various in vitro treatments on the concentration response curves to DAKD in 5-hour incubated HUV rings

TreatmentPeriod (h)pEC50Emaxan
ControlTreatedControlTreatedControlTreated
BIX02188 (1 µM)h
0–58.88 ± 0.048.87 ± 0.0585.30 ± 1.6886.32 ± 1.98117
BIX02188 (10 μM)0–58.88 ± 0.048.08 ± 0.05***85.30 ± 1.6891.74 ± 2.93116
BIX02188 (10 μM)4.75–58.81 ± 0.048.73 ± 0.0886.90 ± 1.9680.71 ± 2.8076
SB203580 (1 µM)0–58.96 ± 0.058.76 ± 0.0588.23 ± 2.0083.52 ± 2.18115
SB203580 (10 µM)0–58.96 ± 0.058.61 ± 0.07**88.23 ± 2.0081.32 ± 2.73117
SB203580 (10 µM)4.75–58.81 ± 0.048.76 ± 0.0586.90 ± 1.9680.58 ± 2.0777
VX-702 (20 nM)0–59.00 ± 0.028.97 ± 0.0877.47 ± 1.1381.15 ± 2.69115
VX-702 (200 nM)0–59.00 ± 0.028.47 ± 0.03***77.47 ± 1.1378.12 ± 1.54117
VX-702 (200 nM)4.75–58.81 ± 0.048.79 ± 0.0986.90 ± 1.9687.96 ± 3.0877
SP600125 (1 µM)0–58.87 ± 0.038.83 ± 0.0389.74 ± 1.4789.01 ± 1.5797
SP600125 (3 µM)0–58.87 ± 0.038.28 ± 0.04***89.74 ± 1.4779.94 ± 1.9197
SP600125 (3 µM)4.75–58.81 ± 0.048.61 ± 0.0486.90 ± 1.9677.23 ± 1.8177
PD184353 (0.1 µM)0–58.85 ± 0.038.94 ± 0.0680.12 ± 1.4474.02 ± 2.13137
PD184353 (1 µM)0–58.85 ± 0.038.75 ± 0.0780.12 ± 1.4475.89 ± 2.40137

  • ↵a Emax is expressed as a percentage of maximum responses obtained with 10 µM 5-HT. Values are expressed as mean ± S.E.M.

  • ↵** P < 0.01; ***P < 0.001, significant differences between pEC50 values.